Clinimetrics Research Associates, Inc. company is a contract research organization (CRO) that provides clinical research services, consulting, project management, data management, and electronic data capture services through most stages of clinical trials. Its services aim to control costs for customers including global biotechnology, pharmaceutical, and medical device companies. It specializes in biotech development, as well as in therapeutic areas such as oncology and cardiology research. Clinimetrics has locations throughout North America. The company is a subsidiary of institutional pharmacy operator Omnicare.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

Cardiovascular Systems, Inc. company was founded in 1989 and is based in Saint Paul, Minnesota. Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing interventional treatment systems for vascular disease. Its primary product, the Diamondback 360°, is a minimally invasive catheter system for the treatment of peripheral arterial disease and a range of plaque types in leg arteries. The Diamondback 360° consists of a single-use catheter that travels over its proprietary ViperWire Guide Wire. The system is used in conjunction with a reusable external control unit.

CPEX Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, licensing, and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its drug delivery technology, CPE-215 technology, enhances permeation and absorption of pharmaceutical molecules across biological membranes such as the skin, nasal mucosa and eye. The company's principal product Testim, a gel for testosterone replacement therapy is licensed to Auxilium Pharmaceuticals, Inc. that markets the product in the United States, Europe, and other countries. It also holds U.S. and international patents, and other proprietary rights to technologies that facilitate the absorption of drugs. In addition, CPEX Pharmaceuticals, Inc. is developing an intranasal insulin product candidate, Nasulin, which is in Phase II clinical trials. The company was incorporated in 2007 and is headquartered in Exeter, New Hampshire.

Pharmos Corporation was founded in 1990 and is headquartered in Iselin, New Jersey. Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutic drugs to treat a range of diseases of the nervous system in the United States and Israel. It focuses on the diseases of the nervous system, such as the disorders of the brain-gut axis, pain/inflammation, and autoimmune disorders. Pharmos's lead product candidate includes dextofisopam, a non-serotonergic agent, which is in Phase IIb clinical trials for the treatment of irritable bowel syndrome (IBS). Its product pipeline also includes VPI-013 that completed Phase IIa testing for the treatment of female sexual dysfunction and neuropathic pain; CB2-selective cannabinoids for the treatment of inflammatory/autoimmune diseases; and Tianeptine, which is in Phase I clinical trials for the treatment of IBS and functional dyspepsia. In addition, Pharmos Corporation's products under development comprise Cannabinor that has completed two Phase IIa proof of principle trials for treating pain; and NanoEmulsion drug delivery system, which is in Phase IIa clinical trial for the treatment of knee osteoarthritis. Pharmos's therapeutic drugs are also used to treat autoimmune disorders.

Forest Pharmaceuticals, Inc. (FPI) can help you see the pharmaceuticals amidst the trees. The company develops, manufactures, and distributes a variety of prescription and OTC pharmaceutical products, including both branded and generic versions. Its product line includes Aerobid (asthma), Celexa and Lexapro (depression), Cervidil (cervical ripening), Tiazac (hypertension), and Namenda (Alzheimer's disease). FPI's products are marketed to physicians, hospitals, pharmacies, and managed care organizations in the US and Puerto Rico. The company, which operates manufacturing and packaging facilities in Missouri and Ohio, is a subsidiary of Forest Laboratories.

NanoBio is trying to put its NanoStat antimicrobial nanoemulsion technology to work enabling drugs that treat topical and mucosal diseases. The firm's nanoemulsions are formulated to destroy such bacteria as "E. coli", as well as fungi, spores, and viral invaders. NanoBio's two lead candidates are in development to treat cold sores and nail fungus. Other candidates target acne, genital herpes, herpes zoster (better known as shingles), drug-resistant bacterial infections, and viral respiratory infections. NanoBio is also exploring how to use its technology to develop vaccines for hepatitis B and influenza.

Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

Dey, L.P. company, a subsidiary of generic drugmaker Mylan, makes prescription drugs for the treatment of allergies and respiratory diseases. Dey markets EpiPen autoinjectors, used by patients to self-administer epinephrine for severe allergic reactions. Its premeasured unit-dose inhalation products include treatments for asthma and chronic obstructive pulmonary disease (COPD). These treatments, called bronchodialators, are used in air-driven breathing devices called nebulizers and include branded DuoNeb and Perforomist products. It also offers several non-branded generic nebulizer treatments. A direct sales force markets Dey's products to doctors, pharmacies, and wholesalers.

Roche Holding (UK) is the holding company for Roche Products Limited and Roche Diagnostics Limited. The two UK subsidiaries develop and manufacture various products and equipment for the diagnosis and treatment of disease. Its pharmaceuticals include Copegus, a hepatitis C therapy; HIV inhibitor Fuzeon; and breast cancer therapy Herceptin. The firm's diagnostics arm makes a variety of consumer and professional tests, including Accu-Chek glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.